TP53 and urinary bladder carcinoma: Our data indicated that high proportion (~ 82%) of our bladder cancer cohort harbor p53 mutation (data not published) which may suggest the involvement of p53 mutation in association with GSTP1 in the risk of bladder cancer development and drug resistance.